Clinical Research Directory
Browse clinical research sites, groups, and studies.
Exparel vs Block for ACL Reconstruction
Sponsor: Rothman Institute Orthopaedics
Summary
Liposomal bupivacaine or Exparel (Pacira Biosciences) is a long-lasting nonopioid analgesic that was initially utilized as an infiltrative agent but has more recently become U.S. Food and Drug Administration (FDA) approved for use in interscalene brachial plexus nerve blockade as well as infiltrative blockade. Delivery in this form is reported to provide up to 72 hours of extended-release bupivacaine. Exparel's use as a regional anesthetic has also become increasingly common and has shown promise when utilized in Anterior Cruciate Ligament (ACL) reconstruction.
Official title: Single-Shot Liposomal Bupivacaine vs. Liposomal Bupivacaine Combined With Dexamethasone Following Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
154
Start Date
2023-08-21
Completion Date
2024-10-30
Last Updated
2024-06-21
Healthy Volunteers
Yes
Conditions
Interventions
Exparel 30 mL
30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
0.5% bupivacaine
5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
Dexamethasone
10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
iPACK block
iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
Locations (1)
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States